Concepts (169)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Apolipoproteins | 13 | 2019 | 200 | 2.600 |
Why?
|
| Lipoproteins, HDL | 12 | 2016 | 251 | 2.520 |
Why?
|
| African Americans | 20 | 2019 | 1428 | 1.770 |
Why?
|
| Kidney Diseases | 6 | 2019 | 249 | 1.410 |
Why?
|
| Diabetic Nephropathies | 3 | 2016 | 224 | 1.180 |
Why?
|
| Polymorphism, Single Nucleotide | 12 | 2018 | 1067 | 1.060 |
Why?
|
| Kidney | 3 | 2019 | 515 | 0.980 |
Why?
|
| Kidney Failure, Chronic | 7 | 2019 | 540 | 0.970 |
Why?
|
| Acetyl-CoA Carboxylase | 3 | 2013 | 23 | 0.920 |
Why?
|
| Genetic Predisposition to Disease | 10 | 2018 | 835 | 0.870 |
Why?
|
| Kidney Transplantation | 4 | 2019 | 515 | 0.750 |
Why?
|
| Diabetes Mellitus, Type 2 | 8 | 2017 | 1424 | 0.620 |
Why?
|
| Sepsis | 1 | 2019 | 158 | 0.620 |
Why?
|
| Mitochondrial Diseases | 1 | 2016 | 11 | 0.570 |
Why?
|
| Renal Dialysis | 3 | 2019 | 279 | 0.560 |
Why?
|
| RNA, Messenger | 3 | 2014 | 508 | 0.540 |
Why?
|
| Mesangial Cells | 1 | 2014 | 10 | 0.480 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2019 | 288 | 0.480 |
Why?
|
| Kidney Glomerulus | 1 | 2014 | 30 | 0.470 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2014 | 40 | 0.470 |
Why?
|
| Genotype | 7 | 2019 | 727 | 0.470 |
Why?
|
| Risk Factors | 10 | 2019 | 3851 | 0.430 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2013 | 80 | 0.420 |
Why?
|
| Humans | 30 | 2019 | 31836 | 0.400 |
Why?
|
| Adipose Tissue | 5 | 2016 | 345 | 0.400 |
Why?
|
| Metabolism | 1 | 2011 | 7 | 0.400 |
Why?
|
| Obesity | 3 | 2016 | 1158 | 0.390 |
Why?
|
| Tissue Donors | 3 | 2019 | 198 | 0.380 |
Why?
|
| Graft Survival | 3 | 2019 | 314 | 0.380 |
Why?
|
| Genome-Wide Association Study | 6 | 2018 | 549 | 0.380 |
Why?
|
| Middle Aged | 18 | 2018 | 11824 | 0.370 |
Why?
|
| Fatty Acids | 1 | 2010 | 97 | 0.350 |
Why?
|
| Body Mass Index | 1 | 2013 | 916 | 0.340 |
Why?
|
| Genetic Association Studies | 4 | 2015 | 145 | 0.290 |
Why?
|
| Lupus Nephritis | 2 | 2018 | 30 | 0.280 |
Why?
|
| Glomerulonephritis | 2 | 2018 | 21 | 0.270 |
Why?
|
| Gene Expression Regulation | 4 | 2016 | 493 | 0.270 |
Why?
|
| Tumor Virus Infections | 2 | 2018 | 21 | 0.270 |
Why?
|
| Polyomavirus Infections | 2 | 2018 | 21 | 0.270 |
Why?
|
| Male | 17 | 2018 | 19091 | 0.270 |
Why?
|
| Hepatocytes | 2 | 2017 | 76 | 0.260 |
Why?
|
| Female | 16 | 2018 | 19859 | 0.260 |
Why?
|
| European Continental Ancestry Group | 5 | 2017 | 1169 | 0.240 |
Why?
|
| Adult | 12 | 2016 | 9327 | 0.240 |
Why?
|
| Genetic Variation | 2 | 2015 | 245 | 0.240 |
Why?
|
| Mice | 4 | 2019 | 2476 | 0.220 |
Why?
|
| Cells, Cultured | 2 | 2016 | 833 | 0.220 |
Why?
|
| African Continental Ancestry Group | 2 | 2016 | 363 | 0.220 |
Why?
|
| Insulin Resistance | 3 | 2017 | 461 | 0.210 |
Why?
|
| Risk | 3 | 2019 | 318 | 0.210 |
Why?
|
| Liver | 2 | 2017 | 482 | 0.200 |
Why?
|
| Disease Progression | 3 | 2019 | 593 | 0.200 |
Why?
|
| Neoplasm Proteins | 2 | 2013 | 148 | 0.200 |
Why?
|
| Muscle, Skeletal | 2 | 2016 | 513 | 0.170 |
Why?
|
| Alleles | 1 | 2019 | 248 | 0.170 |
Why?
|
| Renal Insufficiency | 1 | 2019 | 58 | 0.160 |
Why?
|
| Mice, Transgenic | 1 | 2019 | 261 | 0.160 |
Why?
|
| Quantitative Trait Loci | 2 | 2016 | 140 | 0.150 |
Why?
|
| JC Virus | 2 | 2018 | 20 | 0.150 |
Why?
|
| Fibroblast Growth Factors | 1 | 2017 | 35 | 0.150 |
Why?
|
| Animals | 4 | 2019 | 7450 | 0.150 |
Why?
|
| Lipogenesis | 1 | 2017 | 18 | 0.150 |
Why?
|
| DNA | 1 | 2018 | 227 | 0.140 |
Why?
|
| Continental Population Groups | 1 | 2018 | 236 | 0.140 |
Why?
|
| Glomerular Filtration Rate | 5 | 2017 | 305 | 0.140 |
Why?
|
| Aged | 6 | 2016 | 10288 | 0.140 |
Why?
|
| Mutation | 1 | 2018 | 487 | 0.130 |
Why?
|
| Muscles | 1 | 2016 | 62 | 0.130 |
Why?
|
| Treatment Outcome | 3 | 2019 | 3294 | 0.130 |
Why?
|
| Mice, Knockout | 2 | 2017 | 444 | 0.130 |
Why?
|
| Cholesterol | 1 | 2017 | 251 | 0.130 |
Why?
|
| Caveolin 1 | 1 | 2015 | 13 | 0.130 |
Why?
|
| Molecular Motor Proteins | 1 | 2015 | 58 | 0.130 |
Why?
|
| Myosin Heavy Chains | 1 | 2015 | 89 | 0.120 |
Why?
|
| Proteomics | 1 | 2015 | 94 | 0.120 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2015 | 61 | 0.120 |
Why?
|
| Survival Analysis | 1 | 2016 | 487 | 0.120 |
Why?
|
| Podocytes | 1 | 2014 | 20 | 0.120 |
Why?
|
| Microscopy, Fluorescence | 1 | 2014 | 88 | 0.120 |
Why?
|
| Autoantigens | 1 | 2013 | 16 | 0.110 |
Why?
|
| Liver Neoplasms | 1 | 2015 | 159 | 0.110 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2013 | 73 | 0.110 |
Why?
|
| Epithelial Cells | 1 | 2014 | 142 | 0.110 |
Why?
|
| Signal Transduction | 1 | 2017 | 687 | 0.110 |
Why?
|
| Cell Line | 1 | 2014 | 434 | 0.110 |
Why?
|
| Biopsy | 1 | 2014 | 260 | 0.110 |
Why?
|
| Nephrectomy | 1 | 2014 | 123 | 0.110 |
Why?
|
| Demography | 1 | 2013 | 110 | 0.110 |
Why?
|
| Indians, North American | 1 | 2013 | 109 | 0.110 |
Why?
|
| Triglycerides | 1 | 2013 | 230 | 0.100 |
Why?
|
| Membrane Proteins | 1 | 2013 | 257 | 0.100 |
Why?
|
| Adolescent | 3 | 2016 | 3511 | 0.100 |
Why?
|
| Thioredoxin Reductase 1 | 1 | 2011 | 2 | 0.100 |
Why?
|
| Nuclear Proteins | 1 | 2011 | 74 | 0.100 |
Why?
|
| Environmental Exposure | 1 | 2012 | 90 | 0.100 |
Why?
|
| Diabetic Angiopathies | 1 | 2012 | 143 | 0.100 |
Why?
|
| Kidney Function Tests | 3 | 2017 | 106 | 0.090 |
Why?
|
| Cardiovascular Diseases | 2 | 2016 | 1122 | 0.090 |
Why?
|
| Carrier Proteins | 1 | 2011 | 137 | 0.090 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 771 | 0.090 |
Why?
|
| Neovascularization, Physiologic | 1 | 2011 | 110 | 0.090 |
Why?
|
| Case-Control Studies | 3 | 2018 | 895 | 0.090 |
Why?
|
| Graft Rejection | 1 | 2011 | 237 | 0.090 |
Why?
|
| Gene Expression | 1 | 2011 | 334 | 0.090 |
Why?
|
| Proportional Hazards Models | 3 | 2017 | 756 | 0.090 |
Why?
|
| Oxidation-Reduction | 1 | 2010 | 268 | 0.090 |
Why?
|
| Oxidative Stress | 1 | 2011 | 229 | 0.080 |
Why?
|
| Phenotype | 3 | 2016 | 635 | 0.080 |
Why?
|
| Young Adult | 4 | 2016 | 2603 | 0.070 |
Why?
|
| Creatinine | 2 | 2017 | 195 | 0.070 |
Why?
|
| United States | 4 | 2017 | 3925 | 0.070 |
Why?
|
| Albuminuria | 2 | 2017 | 181 | 0.060 |
Why?
|
| Chi-Square Distribution | 2 | 2016 | 298 | 0.060 |
Why?
|
| Prevalence | 2 | 2017 | 979 | 0.050 |
Why?
|
| Time Factors | 2 | 2016 | 2146 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 2271 | 0.040 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2018 | 5 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 72 | 0.040 |
Why?
|
| Morbidity | 1 | 2018 | 99 | 0.040 |
Why?
|
| Gene Deletion | 1 | 2017 | 66 | 0.040 |
Why?
|
| Coronary Vessels | 1 | 2017 | 158 | 0.030 |
Why?
|
| Glucose Tolerance Test | 1 | 2016 | 125 | 0.030 |
Why?
|
| AIDS-Associated Nephropathy | 1 | 2015 | 11 | 0.030 |
Why?
|
| Nephritis | 1 | 2015 | 15 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2016 | 193 | 0.030 |
Why?
|
| Hypertension, Renal | 1 | 2015 | 29 | 0.030 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2015 | 19 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 135 | 0.030 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2015 | 38 | 0.030 |
Why?
|
| Anemia, Sickle Cell | 1 | 2015 | 43 | 0.030 |
Why?
|
| Tissue and Organ Procurement | 1 | 2016 | 93 | 0.030 |
Why?
|
| Autophagy | 1 | 2015 | 52 | 0.030 |
Why?
|
| Donor Selection | 1 | 2015 | 33 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2015 | 283 | 0.030 |
Why?
|
| Haplotypes | 1 | 2015 | 220 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 355 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2016 | 470 | 0.030 |
Why?
|
| Registries | 1 | 2016 | 295 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 686 | 0.030 |
Why?
|
| Bone Morphogenetic Protein 4 | 1 | 2013 | 13 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2015 | 261 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 504 | 0.030 |
Why?
|
| Epistasis, Genetic | 1 | 2013 | 44 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2013 | 220 | 0.030 |
Why?
|
| Cystatin C | 1 | 2013 | 31 | 0.030 |
Why?
|
| Nonlinear Dynamics | 1 | 2013 | 51 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2013 | 52 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2017 | 1824 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2015 | 725 | 0.030 |
Why?
|
| Age Factors | 1 | 2016 | 1187 | 0.030 |
Why?
|
| Cognition | 1 | 2016 | 551 | 0.030 |
Why?
|
| Linear Models | 1 | 2013 | 449 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2016 | 843 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2011 | 50 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 1527 | 0.020 |
Why?
|
| Atherosclerosis | 1 | 2017 | 767 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2011 | 186 | 0.020 |
Why?
|
| Rats | 1 | 2015 | 1586 | 0.020 |
Why?
|
| Family | 1 | 2011 | 117 | 0.020 |
Why?
|
| Subcutaneous Fat | 1 | 2011 | 47 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2011 | 142 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2011 | 189 | 0.020 |
Why?
|
| Genomics | 1 | 2011 | 84 | 0.020 |
Why?
|
| Genome, Human | 1 | 2011 | 132 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 1323 | 0.020 |
Why?
|
| Hypertension | 1 | 2016 | 956 | 0.020 |
Why?
|
| Brain | 1 | 2016 | 949 | 0.020 |
Why?
|
| North Carolina | 1 | 2013 | 1514 | 0.020 |
Why?
|
| Prognosis | 1 | 2011 | 1498 | 0.020 |
Why?
|